1. Regulatory aspects of the development of drugs for metabolic bone diseases - FDA and EMA perspective.
- Author
-
Kehoe T, Blind E, and Janssen H
- Subjects
- Biosimilar Pharmaceuticals therapeutic use, Bone Density Conservation Agents adverse effects, Bone Diseases, Metabolic diagnosis, Bone Diseases, Metabolic physiopathology, Drugs, Generic therapeutic use, Europe, Humans, Patient Safety, Policy Making, Product Surveillance, Postmarketing, Risk Assessment, Treatment Outcome, United States, Bone Density Conservation Agents therapeutic use, Bone Diseases, Metabolic drug therapy, Bone Remodeling drug effects, Drug Approval legislation & jurisprudence, Drug Development legislation & jurisprudence, Government Regulation, United States Food and Drug Administration legislation & jurisprudence
- Abstract
Regulation of medicines involves complex scientific and public health policies which are reflected in the regulatory approaches used by the European Medicines Agency and the United States Food and Drug Administration for the approval of products developed for metabolic bone diseases. For osteoporosis therapies, utilized by many patients, the approaches and existing guidance for product development of both agencies are similar; confirmatory studies for the approval of osteoporosis products can rely on well-defined efficacy outcome parameters. Therapeutics for rare bone diseases, a rapidly expanding area, often require an individualized regulatory approach. This review outlines key aspects of these regulatory approaches applied by the two agencies for products for metabolic bone diseases., (© 2018 The British Pharmacological Society.)
- Published
- 2019
- Full Text
- View/download PDF